Skip to main content

Mostafa Adam S.'s Form 4 filing

X4 Pharmaceuticals, Inc (XFOR) · filed Jun 17, 2022

Accession no.
0001628280-22-017438
Filed
Jun 17, 2022
Trade date
Jun 16, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 1 non-derivative transaction. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mostafa Adam S.CIK 0001738081Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 16, 2022Common StockSSaleDisposed−5,416–F2–192,808Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.03 to $1.13, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)